Dual Target CAR-T Cells in B-cell Lymphoma
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .
Lymphoma, B-Cell|Relapse/Recurrence|Refractory Lymphoma|Dual-target CAR-T Cells
BIOLOGICAL: dual target CAR-T cell therapy
Complete remission rate, All visible lesions disappeared completely and maintained at least 4 weeks., From date of initial treatment to the end of follow up, up to 2 years
Overall survival rate, The proportion of surviving patients at the end of the study., From admission to the end of follow up, up to 2 years
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma . Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected patients received CD19/CD20 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to determine the survival status and follow-up treatment.